Compare Novo Nordisk A/S (NVO) vs Teucrium Soybean Fund (SOYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Teucrium Soybean Fund — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Teucrium Soybean Fund trades at $25.86. The key difference: Novo Nordisk A/S pays a 3.63% dividend while Teucrium Soybean Fund pays none, and Teucrium Soybean Fund is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | SOYB | |
|---|---|---|
Market Cap | $220.53B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $71.70 | $25.88 |
52-Week Low | $35.29 | $21.07 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →
